Search

Your search keyword '"Atrash, Shebli"' showing total 491 results
Start Over Author "Atrash, Shebli"
491 results on '"Atrash, Shebli"'

1. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, Hashmi, Hamza, Hansen, Doris K., Sidana, Surbhi, Ahn, Chul, Peres, Lauren C., Dima, Danai, Freeman, Ciara L., Puglianini, Omar Castaneda, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter M., Shune, Leyla, McGuirk, Joseph P., Simmons, Gary, Sborov, Douglas W., Davis, James A., Kaur, Gurbakhash, Sannareddy, Aishwarya, Ferreri, Christopher J., Gaballa, Mahmoud R., Goldsmith, Scott, Nadeem, Omar, Midha, Shonali, Wagner, Charlotte B., Locke, Frederick L., Patel, Krina K., Khouri, Jack, Anderson, Jr., Larry D., and Lin, Yi

Published
2024
Full Text
View/download PDF

2. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Author

Ferreri, Christopher J., Hildebrandt, Michelle A. T., Hashmi, Hamza, Shune, Leyla O., McGuirk, Joseph P., Sborov, Douglas W., Wagner, Charlotte B., Kocoglu, M. Hakan, Rapoport, Aaron, Atrash, Shebli, Voorhees, Peter M., Khouri, Jack, Dima, Danai, Afrough, Aimaz, Kaur, Gurbakhash, Anderson, Jr., Larry D., Simmons, Gary, Davis, James A., Kalariya, Nilesh, Peres, Lauren C., Lin, Yi, Janakiram, Murali, Nadeem, Omar, Alsina, Melissa, Locke, Frederick L., Sidana, Surbhi, Hansen, Doris K., Patel, Krina K., and Castaneda Puglianini, Omar Alexis

Published
2023
Full Text
View/download PDF

3. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy

Author

Peres, Lauren C., Oswald, Laura B., Dillard, Christen M., De Avila, Gabriel, Nishihori, Taiga, Blue, Brandon J., Freeman, Ciara L., Locke, Frederick L., Alsina, Melissa, Castaneda Puglianini, Omar, Shune, Leyla, Sborov, Douglas W., Wagner, Charlotte, Dima, Danai, Hashmi, Hamza, Davis, James A., Kocoglu, Mehmet H., Badros, Ashraf Z., Atrash, Shebli, Simmons, Gary, Kalariya, Nilesh, Ferreri, Christopher, Anderson, Larry D., Jr, Afrough, Aimaz, Kaur, Gurbakhash, Lin, Yi, Liu, Lawrence, Nadeem, Omar, Voorhees, Peter, Khouri, Jack, McGuirk, Joseph, Sidana, Surbhi, Hansen, Doris K., and Patel, Krina

Published
2024
Full Text
View/download PDF

4. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

Author

Bhutani, Manisha, Foureau, David M., Robinson, Myra, Guo, Fei, Fesenkova, Kateryna, Atrash, Shebli, Paul, Barry, Varga, Cindy, Friend, Reed, Pineda-Roman, Mauricio, Rigby, Katherine, Symanowski, James T., Norek, Sarah, Tucker, Mallory R., Druhan, Lawrence J., Voorhees, Peter M., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

8. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Author

Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Jr, Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, and Kaur, Gurbakhash

Published
2024
Full Text
View/download PDF

11. Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma.

Author

Hamadeh, Issam S., Friend, Reed, Mailankody, Sham, and Atrash, Shebli

Subjects
T-cell exhaustion, CHIMERIC antigen receptors, INCURABLE diseases, MULTIPLE myeloma, T cells
Abstract

Although multiple myeloma is an incurable disease, the past decade has witnessed significant improvement in patient outcomes. This was brought about by the development of T-cell redirection therapies such as chimeric antigen receptor (CAR) T-cells, which can leverage the natural ability of the immune system to fight myeloma cells. The approval of the B-cell maturation antigen (BCMA)-directed CAR T, idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel) has resulted in a paradigm shift in the treatment of relapsed/refractory multiple myeloma. Overall response rates ranging from 73 to 97% are currently achievable. However, the limitations of KarMMa-1 and CARTITUDE-1 studies spurred the generation of real-world data to provide some insights into the effectiveness of ide-cel and cilta-cel among patients who were excluded from clinical trials, particularly those who received prior BCMA-targeted or other T-cell redirection therapies. Despite their unprecedented clinical efficacy in heavily pretreated patients, responses to CAR T remain non-durable. Although the underlying mechanisms of resistance to these agents haven't been fully elucidated, studies have suggested that resistance patterns could be multifaceted, implicating T-cell exhaustion and tumor intrinsic mechanisms such as BCMA target loss, upregulation of gammasecretase, and others. Herein, we provide a succinct overview of the development of CAR T-cells, manufacturing process, and associated toxicities/complications. In this review, we also recapitulate the existing literature pertaining MM CAR-T as well as emerging data from some of the ongoing clinical trials designed to mitigate the shortcomings of these agents, and improve the clinical efficacy of CAR T, especially in the relapsed/refractory setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

Author

Ehsan, Hamid, primary, Robinson, Myra, additional, Voorhees, Peter M., additional, Cassetta, Kristen, additional, Borden, Shanice, additional, Atrash, Shebli, additional, Bhutani, Manisha, additional, Varga, Cindy, additional, Pineda-Roman, Mauricio, additional, Friend, Reed, additional, and Paul, Barry A., additional

Published
2024
Full Text
View/download PDF

14. Idecabtagene Vicleucel (ide-cel) Chimeric Antigen Receptor T-Cell for Plasma Cell Leukemia (PCL): A Multicenter Experience

Author

Fortuna, Gliceida Maria Galarza, primary, Sidana, Surbhi, additional, Hovanky, Vanna, additional, Khouri, Jack, additional, Dima, Danai, additional, Kocoglu, Mehmet H., additional, Forsberg, Peter, additional, Ferreri, Christopher, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Hashmi, Hamza, additional, Davis, James, additional, Gaballa, Mahmoud, additional, Anto, Eric, additional, De Avila, Gabe, additional, Peres, Lauren, additional, Patel, Krina K., additional, Hansen, Doris K, additional, and Sborov, Douglas, additional

Published
2024
Full Text
View/download PDF

15. The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023

Author

Atallah, Rawan, primary, Saif, Md Saiful Islam, additional, Danai, Dima, additional, Shrestha, Anuj, additional, Anwer, Faiz, additional, Mushtaq, Muhammad Umair, additional, Lutfi, Forat, additional, Shune, Leyla, additional, Hashmi, Hamza, additional, Ganguly, Siddhartha MD, additional, McGuirk, Joseph P, additional, Atrash, Shebli, additional, Abdallah, Al-Ola, additional, Banerjee, Rahul, additional, Ahmed, Nausheen, additional, and Logan, Emerson, additional

Published
2024
Full Text
View/download PDF

16. VD-PACE As Salvage and Bridging Therapy to Transplant and Cellular Therapy in Triple Class Relapsed/Refractory Multiple Myeloma

Author

Venkatesh, Priyanka, primary, Bellman, Polina, additional, Shatnawi, Sara, additional, Shatnawi, Yara, additional, Shaikh, Hira, additional, Strouse, Christopher Sun, additional, Atrash, Shebli, additional, Hashmi, Hamza, additional, Mushtaq, Muhammad Umair, additional, Ahmed, Nausheen, additional, Mahmoudjafari, Zahra, additional, Abdallah, Al-Ola, additional, and Shune, Leyla, additional

Published
2024
Full Text
View/download PDF

17. Patient Outcomes Following First and Second Exposure to BCMA-Directed Therapies Including CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Author

Snyder, Jordan, primary, Bellman, Polina, additional, Alsaddi, Zain, additional, Alkharabsheh, Omar, additional, Paul, Barry, additional, Hashmi, Hamza, additional, Lutfi, Forat, additional, Ahmed, Nausheen, additional, Mahmoudjafari, Zahra, additional, Abdallah, Al-Ola, additional, and Atrash, Shebli, additional

Published
2024
Full Text
View/download PDF

18. Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Author

Soomro, Mohammad Ahsen, primary, Atrash, Shebli, additional, Rashid, Aliya, additional, Wesson, William, additional, Hashmi, Mr. Hamza, additional, Afrough, Aimaz, additional, Skikne, Barry S., additional, Lutfi, Forat, additional, Mushtaq, Muhammad Umair, additional, Abdallah, Al-Ola, additional, Ahmed, Nausheen, additional, and Khaliq, Aroog, additional

Published
2024
Full Text
View/download PDF

19. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience

Author

Varga, Cindy, primary, Robinson, Myra, additional, Ehsan, Hamid, additional, Roberts, Danielle, additional, Dicamillo, Sara, additional, Gupta, Vikas, additional, Borden, Shanice, additional, Bhutani, Manisha, additional, Paul, Barry A., additional, Atrash, Shebli, additional, Ferreri, Christopher, additional, Nooka, Ajay K., additional, Voorhees, Peter M., additional, and Joseph, Nisha, additional

Published
2024
Full Text
View/download PDF

20. Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.

Author

Janakiram, Murali, primary, Khouri, Jack, additional, Castaneda, Omar, additional, Shune, Leyla, additional, Dima, Danai, additional, Kaur, Gurbakhash, additional, De Avila, Gabe, additional, Gaballa, Mahmoud, additional, Midha, Shonali, additional, Davis, James, additional, Wagner, Charlotte, additional, McGuirk, Joseph P, additional, Forsberg, Peter, additional, Reshef, Ran, additional, Lin, Yi, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Davila, Dr. Marco L., additional, Kocoglu, Mehmet H., additional, Sborov, Douglas, additional, Htut, Myo, additional, Hashmi, Hamza, additional, Sidana, Surbhi, additional, Chowdhury, Arnab, additional, Patel, Krina K., additional, Hansen, Doris K, additional, and Atrash, Shebli, additional

Published
2024
Full Text
View/download PDF

21. The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally

Author

Atallah, Rawan, primary, Shatnawi, Yara, additional, Mammadzadeh, Aytaj, additional, Hashmi, Shahrukh K, additional, Shabeeha, Rana, additional, Mushtaq, Muhammad Umair, additional, Mohamed, Benlazar, additional, Desai, Nihar, additional, Carneiro, Thiago Xavier, additional, Popat, Rakesh, additional, McGuirk, Joseph P, additional, Atrash, Shebli, additional, Mahmoudjafari, Zahra, additional, Logan, Emerson, additional, Abdallah, Al-Ola, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

23. Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, primary, Hashmi, Hamza, additional, Hansen, Doris, additional, Sidana, Surbhi, additional, Ahn, Chul, additional, Peres, Lauren, additional, Dima, Danai, additional, Freeman, Ciara, additional, Puglianini, Omar Castaneda, additional, Kocoglu, Mehmet, additional, Atrash, Shebli, additional, Voorhees, Peter, additional, Shune, Leyla, additional, McGuirk, Joseph, additional, Simmons, Gary, additional, Sborov, Douglas, additional, Davis, James, additional, Kaur, Gurbakash, additional, Sannareddy, Aishwarya, additional, Ferreri, Christopher, additional, Gaballa, Mahmoud, additional, Janakiram, Murali, additional, nadeem, omar, additional, Midha, Shonali, additional, Wagner, Charlotte, additional, Locke, Frederick, additional, Patel, Krina, additional, Khouri, Jack, additional, Anderson, Larry, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

24. Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma

Author

Afrough, Aimaz, primary, Atrash, Shebli, additional, Paul, Barry, additional, Ouchveridze, Evguenia, additional, Ahmed, Nausheen, additional, Mahmoudjafari, Zahra, additional, Bashir, Anam, additional, Alkharabsheh, Omar, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2023
Full Text
View/download PDF

30. P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience

Author

Sidana, Surbhi, primary, Patel, Krina, additional, Peres, Lauren, additional, Bansal, Radhika, additional, Kocoglu, M Hakan, additional, Shune, Leyla, additional, Atrash, Shebli, additional, Smith, Kinaya, additional, Ferreri, Christopher, additional, Dhakal, Binod, additional, Chhabra, Saurabh, additional, Parrondo, Ricardo, additional, Costello, Patrick, additional, Midha, Shonali, additional, Martin, Thomas, additional, Simmons, Gary, additional, Alsina, Melissa, additional, Htut, Myo, additional, Voorhees, Peter, additional, Sborov, Douglas, additional, Khouri, Jack, additional, Wong, Sandy, additional, Janakiram, Murali, additional, Lin, Yi, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

31. P-002 Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the U.S. myeloma CAR T consortium

Author

Afrough, Aimaz, primary, Hashmi, Hamza, additional, Hansen, Doris, additional, Sidana, Surbhi, additional, Ahn, Chul, additional, Dima, Danai, additional, Freeman, Ciara, additional, Puglianini, Omar Castaneda, additional, Kocoglu, M Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter, additional, Shune, Leyla, additional, Simmons, Gary, additional, Sborov, Douglas, additional, Ferreri, Christopher, additional, Wagner, Charlotte, additional, Patel, Krina, additional, Khouri, Jack, additional, Anderson, Larry, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

35. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Author

Hansen, Doris K., primary, Sidana, Surbhi, additional, Peres, Lauren C., additional, Colin Leitzinger, Christelle, additional, Shune, Leyla, additional, Shrewsbury, Alexandria, additional, Gonzalez, Rebecca, additional, Sborov, Douglas W., additional, Wagner, Charlotte, additional, Dima, Danai, additional, Hashmi, Hamza, additional, Kocoglu, Mehmet H., additional, Atrash, Shebli, additional, Simmons, Gary, additional, Kalariya, Nilesh, additional, Ferreri, Christopher, additional, Afrough, Aimaz, additional, Kansagra, Ankit, additional, Voorhees, Peter, additional, Baz, Rachid, additional, Khouri, Jack, additional, Alsina, Melissa, additional, McGuirk, Joseph, additional, Locke, Frederick L., additional, and Patel, Krina K., additional

Published
2023
Full Text
View/download PDF

37. Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone

Author

Alkharabsheh, Omar, primary, Bellman, Polina, additional, Mahmoudjafari, Zahra, additional, Cui, Wei, additional, Atrash, Shebli, additional, Paul, Barry, additional, Hashmi, Hamza, additional, Shune, Leyla, additional, Ahmed, Nausheen, additional, and Abdallah, Al-Ola, additional

Published
2023
Full Text
View/download PDF

38. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience

Author

Sidana, Surbhi, primary, Peres, Lauren, additional, Hashmi, Hamza, additional, Hosoya, Hitomi, additional, Ferreri, Christopher, additional, Atrash, Shebli, additional, Khouri, Jack, additional, Voorhees, Peter M., additional, Dima, Danai, additional, Simmons, Gary Lee, additional, Kalariya, Nilesh, additional, Hovanky, Vanna, additional, Bharadwaj, Sushma, additional, Arai, Sally, additional, Miklos, David B., additional, Wagner, Charlotte, additional, Davis, James, additional, Sborov, Douglas, additional, Nishihori, Taiga, additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Gonzalez, Rebecca, additional, Kocoglu, Mehmet H., additional, Sannareddy, Aishwarya, additional, Afrough, Aimaz, additional, McGuirk, Joseph P., additional, Shune, Leyla, additional, Patel, Krina K., additional, and Hansen, Doris K, additional

Published
2023
Full Text
View/download PDF

39. Bone marrow Ki‐67 index is of prognostic value in newly diagnosed multiple myeloma.

Author

Atrash, Shebli, Robinson, Myra, Taneja, Alankrita, Paul, Barry, Cassetta, Kristen, Ndiaye, Ami, Varga, Cindy, Block, Jared, Lipford, Edward H., Smith, Elton T., McCall, Chad M., Thurston, Virginia, Foureau, David, Usmani, Saad Z., Voorhees, Peter M., and Bhutani, Manisha

Subjects
*BONE marrow, *MULTIPLE myeloma, *KI-67 antigen, *PROGNOSIS, *PROGRESSION-free survival, *PLASMACYTOMA
Abstract

Background: Ki‐67 is an index of proliferative activity and is an established predictive and prognostic marker in multiple malignancies. However, its prognostic relevance in multiple myeloma (MM) is unclear. We investigated the relationship between Ki‐67 expression and survival outcomes in MM in the era of novel therapies. Methods: We interrogated our database to identify patients with MM, newly diagnosed between July 1, 2013 and December 31, 2020, with Ki‐67 expression assessed by immunohistochemistry (IHC) on bone marrow biopsies. Using an established threshold of 5% we defined Ki‐67low (≤5%) and Ki‐67high (>5%) subgroups for association with progression‐free survival (PFS) and overall survival (OS). Results: Of 167 patients included: 53 (31.7%) had Ki‐67high and 114 had Ki‐67low. More patients with R‐ISS 3 had Ki‐67high (22.2% vs. 9.7%). The gain of 1q21 was overrepresented in the Ki‐67high group (28% vs. 8%). Median PFS in the Ki‐67low group was 3.1 years, and in the Ki‐67high group 1.6 years (log‐rank p <.001, HR: 1.9). Median OS was not reached in the Ki‐67low vs. 4.8 years in the Ki‐67high cohort (HR: 1.9; log‐rank test: p =.018). In the multivariable modeling, after adjusting for other risk factors, HR for Ki‐67high versus Ki‐67low was 2.4 (p <.001) for PFS and 2.1 (p =.026) for OS. Conclusions: Our results demonstrate that a high Ki‐67 index (>5%) is an independent prognostic marker associated with worse OS and PFS in newly diagnosed MM. IHC staining for Ki‐67 on bone marrow biopsies could be easily adopted as a prognostic biomarker for MM in economically constrained healthcare settings. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)

Author

Bellman, Polina, primary, Cui, Wei, additional, Mahmoudjafari, Zahra, additional, Atrash, Shebli, additional, Paul, Barry, additional, Hashmi, Hamza, additional, Banderudrappagari, Rajesh, additional, Shune, Leyla O., additional, Abdallah, Al-Ola, additional, and Ahmed, Nausheen, additional

Published
2022
Full Text
View/download PDF

42. Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)

Author

Hu, Bei, primary, Atrash, Shebli, additional, Cohen, Leah, additional, Barta, Stefan K., additional, Zhang, Yumeng, additional, Sokol, Lubomir, additional, Ayers, Amy, additional, Malpica Castillo, Luis E, additional, Hwang, Steven R, additional, Bennani, N. Nora, additional, Wada, David, additional, Tun, Aung M, additional, Moyo, Tamara K., additional, Ghosh, Nilanjan, additional, and Shinohara, Michi M, additional

Published
2022
Full Text
View/download PDF

43. Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Author

Bhutani, Manisha, primary, Robinson, Myra, additional, Paul, Barry, additional, Atrash, Shebli, additional, Varga, Cindy, additional, Begic, Xhevahire, additional, Foureau, David M, additional, Pineda-Roman, Mauricio, additional, Koya, Brinda, additional, Norek, Sarah, additional, Sutton, Sara A, additional, Anderson, Michelle B, additional, Acampora, Donna, additional, Symanowski, James T, additional, Voorhees, Peter M., additional, and Usmani, Saad, additional

Published
2022
Full Text
View/download PDF

44. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Author

Ferreri, Christopher J., primary, Hildebrandt, Michelle A.T., additional, Hashmi, Hamza, additional, Shune, Leyla O., additional, McGuirk, Joseph P., additional, Sborov, Douglas W., additional, Wagner, Charlotte B, additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Khouri, Jack, additional, Dima, Danai, additional, Afrough, Aimaz, additional, Sannareddy, Aishwarya, additional, Simmons, Gary, additional, Davis, James, additional, Kalariya, Nilesh, additional, Peres, Lauren C., additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Sidana, Surbhi, additional, Hansen, Doris K., additional, Patel, Krina, additional, and Castaneda Puglianini, Omar Alexis, additional

Published
2022
Full Text
View/download PDF

45. Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients

Author

Ouchveridze, Evguenia, primary, Singh, Chandandeep, additional, Atrash, Shebli, additional, Paul, Barry, additional, Mohan, Meera, additional, Alkharabsheh, Omar, additional, Afrough, Aimaz, additional, Cui, Wei, additional, Mahmoudjafari, Zahra, additional, Abdallah, Al-Ola, additional, and Hashmi, Hamza, additional

Published
2022
Full Text
View/download PDF

46. Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Author

Hashmi, Hamza, primary, Hansen, Doris K., additional, Peres, Lauren C., additional, Castaneda Puglianini, Omar Alexis, additional, Freeman, Ciara L., additional, De Avila, Gabriel, additional, Sidana, Surbhi, additional, Shune, Leyla O., additional, Sborov, Douglas W., additional, Davis, James, additional, Wagner, Charlotte B., additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Simmons, Gary, additional, Ferreri, Christopher J., additional, Kalariya, Nilesh, additional, Sannareddy, Aishwarya, additional, Dima, Danai, additional, Khouri, Jack, additional, McGuirk, Joseph P., additional, Locke, Frederick L., additional, Baz, Rachid C., additional, Patel, Krina, additional, and Alsina, Melissa, additional

Published
2022
Full Text
View/download PDF

47. Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Author

Peres, Lauren C., primary, Oswald, Laura B., additional, Dillard, Christen, additional, De Avila, Gabriel, additional, Nishihori, Taiga, additional, Blue, Brandon J., additional, Freeman, Ciara L., additional, Locke, Frederick L., additional, Alsina, Melissa, additional, Castaneda Puglianini, Omar Alexis, additional, Shune, Leyla O., additional, Sborov, Douglas W., additional, Wagner, Charlotte B, additional, Dima, Danai, additional, Hashmi, Hamza, additional, Davis, James, additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Simmons, Gary, additional, Kalariya, Nilesh, additional, Ferreri, Christopher J., additional, Sannareddy, Aishwarya, additional, Afrough, Aimaz, additional, Voorhees, Peter M., additional, Khouri, Jack, additional, McGuirk, Joseph P., additional, Sidana, Surbhi, additional, Hansen, Doris K., additional, and Patel, Krina, additional

Published
2022
Full Text
View/download PDF

49. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Author

Khouri, Jack, primary, Li, Hong, additional, Hansen, Doris K., additional, Sidana, Surbhi, additional, Shune, Leyla O., additional, DeJarnette, Shaun, additional, Anwer, Faiz, additional, Sborov, Douglas W, additional, Wagner, Charlotte B, additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Valent, Jason, additional, Peres, Lauren C., additional, Hovanky, Vanna, additional, Simmons, Gary, additional, Dima, Danai, additional, Kalariya, Nilesh, additional, Afrough, Aimaz, additional, Kaur, Gurbakhash, additional, Sannareddy, Aishwarya, additional, Ferreri, Christopher J., additional, Davis, James, additional, McGuirk, Joseph P., additional, Locke, Frederick L., additional, Baz, Rachid C., additional, Hamilton, Betty K., additional, Alsina, Melissa, additional, Sauter, Craig S., additional, Hashmi, Hamza, additional, and Patel, Krina, additional

Published
2022
Full Text
View/download PDF

50. Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone

Author

Jain, Jayanshu, primary, Khasawneh, Ghena, additional, Hashmi, Hamza, additional, Mohan, Meera, additional, Mahmoudjafari, Zahra, additional, Cui, Wei, additional, McGuirk, Joseph P., additional, Shune, Leyla O., additional, Ahmed, Nausheen, additional, Abdallah, Al-Ola, additional, and Atrash, Shebli, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results